- Business Wire•yesterday
Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
Bristol-Myers Squibb Company today announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 , a key regulator of metabolism, in patients with biopsy-confirmed nonalcoholic steatohepatitis .
Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday. NASH, a progressive fatty liver disease tied to obesity and diabetes, afflicts about 5 percent of the population and is poised to become the leading cause of liver transplants. The 16-week, 74-patient trial tested the subcutaneously-injected drug, BMS-986036, at two dosing regimens versus placebo in adults whose NASH was confirmed by liver biopsy.
- Business Wire•2 days ago
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Bristol-Myers Squibb Company announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.
BMY : Summary for Bristol-Myers Squibb Company - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||52.62 x 200|
|Ask||53.30 x 200|
|Day's Range||53.15 - 53.71|
|52 Week Range||46.01 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.18|
|Dividend & Yield||1.56 (2.95%)|
|1y Target Est||N/A|